Leerink Partners has reiterated its Market Perform rating and preserved a $41.00 price target on Hims & Hers Health (NYSE:HIMS) following the company’s announcement of a compounded oral semaglutide product. The research house described the launcher as "an extremely logical new product offering" that aligns with Hims & Hers’ existing weight-loss platform and responds to anticipated demand for oral GLP-1 medications.
In its review, Leerink highlighted that the prevailing legal landscape offers an accommodative environment for Hims & Hers to broaden its product mix. The firm suggested the company may evaluate similar launches of weight-loss therapies as the regulatory and market settings evolve.
Leerink indicated it expects the compounded semaglutide pill to play a material role in Hims & Hers’ fiscal year 2026 growth profile, while also acknowledging ongoing variability in the balance between growth and investment. That assessment reflects a view that, although the product could support top-line expansion, the company’s trajectory will continue to depend on execution and the interaction of marketing, supply and cost dynamics.
The research firm also flagged that further detail is likely to emerge on Hims & Hers’ scheduled earnings call on February 23. Based on information currently available, Leerink chose to retain its Market Perform rating.
Leerink’s note arrives against a backdrop of strong performance from established players in the obesity and weight-loss market. The report points to Eli Lilly as an example, noting the company delivered 44.7% revenue growth in its most recent fiscal year.
Eli Lilly’s own quarterly disclosure for fourth-quarter 2025 showed earnings per share of $7.54, topping the $7.20 consensus forecast. Revenue for the quarter was $19.3 billion, above the $17.87 billion analysts had expected. The company issued fiscal year 2026 guidance projecting revenue between $80 billion and $83 billion and non-GAAP EPS in the range of $33.50 to $35.00, both of which outpaced analyst consensus.
Market participants responded with continued buy-side endorsements: Deutsche Bank reiterated a Buy rating with a $1,200.00 price target on Eli Lilly, and Truist Securities sustained its Buy recommendation with a $1,281.00 target, citing the company’s leadership position in obesity treatments.
Within that competitive context, Hims & Hers expanded its weight-loss offerings by launching a compounded version of Novo Nordisk’s Wegovy pill. That move has drawn scrutiny from some analysts. Wolfe Research, for example, raised legal questions about Hims & Hers’ ability to market the oral semaglutide product given the absence of a supply shortage for Novo Nordisk’s semaglutide.
Leerink’s decision to hold the Market Perform rating captures the balance of potential benefit from the new pill against remaining uncertainties tied to legal considerations, market positioning and the company’s investment choices. Investors are likely to look to the February 23 earnings call for additional color on rollout plans and expected financial impact.